Oxfendazole Development Group
Blue Bell, Pennsylvania
B-Health Score
52B-
Financial Health Score
8-metric score across financial health, operational efficiency, and resilience. Based on IRS Form 990 filing data.
Average
💰
$59K
Total Revenue
📊
$605K
Total Expenses
🏦
$1.1M
Net Assets
📋
N/A
Total Liabilities
Financial Trends
5-Year Trend Analysis
Financial Health Indicators
Revenue Growth
-96.6%
Year-over-year change (2022 → 2023)
Net Margin
-933.3%
Revenue minus expenses as % of revenue
Filing History
4 filings on record| Year | Revenue | Expenses | Assets | |
|---|---|---|---|---|
| 2023 | $58,517↓97% | $604,664↑1319% | $1,146,889↓33% | |
| 2022 | $1,710,127↑18422% | $42,614↑204% | $1,721,909↑34373% | — |
| 2018 | $9,233↓91% | $14,004↓85% | $4,995↓49% | — |
| 2017 | $97,653 | $92,121 | $9,766 | — |
Frequently Asked Questions
What does Oxfendazole Development Group do?▼
Oxfendazole Development Group is a medical research nonprofit organization based in Pennsylvania. It is classified under NTEE code H80 and is registered as a 501(c) tax-exempt organization with the IRS.
Is Oxfendazole Development Group financially healthy?▼
Financial health scoring requires Form 990 filing data. Check back as we process more filings for Oxfendazole Development Group.
How much revenue does Oxfendazole Development Group generate?▼
Oxfendazole Development Group reports $23K in annual revenue and holds $318K in total assets, based on IRS filings.
Similar Organizations
Explore more organizations in the Medical Research category, or browse all nonprofits in Pennsylvania.